Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Commentary on September 1985 NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer.

E M Greenspan

    Cancer Investigation
    |January 1, 1986
    PubMed
    Summary

    Conservative breast cancer chemotherapy guidelines may cause premature deaths. Updated recommendations for high-risk patients and tamoxifen for Stage I survivors could save thousands of lives annually.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    New chemoimmunotherapy: courtesy of a more flexible Food and Drug Administration.

    Cancer investigation·1999
    Same author

    Tamoxifen for the prevention of breast cancer.

    The American journal of medicine·1996
    Same author

    Breast cancer chemotherapy after fifty years: more cures and less mutilation.

    The Mount Sinai journal of medicine, New York·1996
    Same author

    Breast cancer.

    Lancet (London, England)·1994
    Same author

    Tamoxifen chemoprevention--are we throwing out the baby with the bathwater?

    Cancer investigation·1994
    Same author

    Chemotherapy for angiosarcoma of the breast: case report of 30-year survival and analysis of the literature.

    Cancer investigation·1994

    Area of Science:

    • Oncology
    • Clinical Trials
    • Public Health

    Background:

    • The 1985 NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer provided conservative recommendations.
    • Current oncological practice, however, often deviates from these guidelines, particularly for high-risk postmenopausal patients.

    Purpose of the Study:

    • To evaluate the impact of the 1985 NIH Consensus recommendations on breast cancer treatment outcomes.
    • To advocate for updated guidelines that incorporate current evidence on adjuvant chemotherapy and tamoxifen efficacy.

    Main Methods:

    • Review of existing clinical trial data on adjuvant chemotherapy and tamoxifen for breast cancer.
    • Analysis of survey data on current practices among American oncologists.
    • Comparison of Consensus recommendations with established survival benefits.

    Related Experiment Videos

    Main Results:

    • The 1985 recommendations may lead to preventable deaths by not fully utilizing adjuvant chemotherapy for high-risk patients.
    • Tamoxifen demonstrates survival benefits for both Stage I and Stage II postmenopausal patients.
    • Ongoing studies indicate significant disease-free survival improvements (10-27%) with chemotherapy for high-risk women.

    Conclusions:

    • Updated guidelines incorporating aggressive chemotherapy for high-risk patients and tamoxifen for Stage I patients could save 10,000-15,000 lives annually in the US.
    • The Consensus Conference missed opportunities to encourage chemoprevention trials and improve survival rates.
    • More realistic recommendations are needed to align with current oncological practice and maximize patient survival.